Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2003
09/17/2003CN1443064A Administration of thiol-based chemoprotectant compound
09/17/2003CN1443063A Water soluble microflake through air gap and process thereof
09/17/2003CN1442440A Binding agent of hydrophilic polymer-glutamic acid oligopeptide and medicinal molecular, composition containing said binding agent and use
09/17/2003CN1442201A Compound containing osteoclast formation inhibiting factor and polysaccharide
09/17/2003CN1442133A Ultrafine fiber medicine dosage form and its preparation method
09/17/2003CN1442127A Water in oil emulsified composition
09/17/2003CN1121238C Novel cyclosporine preparation forms for oral administration of simple composition and high bio availability and process for producing them
09/17/2003CN1121223C Freeze dried composition containing glycosphingolipid and process for producing the same
09/17/2003CN1121219C Novel process for manufacturing paroxetine solid dispersions
09/17/2003CN1121213C Method of preparing sustained release compositions
09/17/2003CN1121211C Detergent composition for skin
09/17/2003CN1121153C Use of carotenoid aggregates as colorants
09/16/2003US6620814 Mixture with partially neutralized pH-dependent binder; antiarrhythmia agents; cardiovascular disorders, myocardium infarction
09/16/2003US6620805 Drug delivery of antihepatitis viricide to hepatocytes
09/16/2003US6620795 Expressing an exogenously supplied gene in cells of the airway are disclosed. Lipid carrier-nucleic acid complexes or nucleic acid abre are prepared then delivered via aerosol or systemically to the lung abre or lung plus extrapulmonary
09/16/2003US6620788 Enteral sorbefacients
09/16/2003US6620781 Glycopeptide carboxy-saccharide derivatives
09/16/2003US6620773 Foaming oil preparation and its use
09/16/2003US6620439 Chrono delivery formulations and method of use thereof
09/16/2003US6620435 Compositions for topical application of therapeutic agents
09/16/2003US6620434 Sustained release dosage form unit having latex coating and method of making the same
09/16/2003US6620433 Dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications
09/16/2003US6620429 Free active substance base is liberated, during the manufacture of the system, from active substance salts by conversion with a basic alkaline metal salt
09/16/2003US6620422 Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period
09/16/2003US6620420 Cosmetic or dermatological application
09/16/2003US6620407 Solid polymer particles having hydrophilic and lipophilic properties
09/16/2003US6620314 Production of pyrogen controlled water
09/16/2003US6620194 Drug coating with topcoat
09/16/2003CA2329875C Matrices formed of polymer and hydrophobic compounds for use in drug delivery
09/16/2003CA2267096C Pharmaceutical microspheres of valproic acid for oral administration
09/16/2003CA2140252C A snow grooming device
09/16/2003CA2108288C Liposomal cyclosporin formulation and process for the preparation thereof
09/16/2003CA2103371C Targeted delivery of genes encoding secretory proteins
09/12/2003WO2003074687A1 System and method for the production of recombinant glycosylated proteins in a prokaryotic host
09/12/2003WO2003074654A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/12/2003WO2003074622A1 Refrigerant compositions, refrigerant auxiliary compositions and uses thereof
09/12/2003WO2003074586A1 Compound of hydrophilic polymer-polycarboxyl oligopeptide and medicines, medical composite comprising above compound and use of above compound in medicimes
09/12/2003WO2003074569A2 Bispecific antibody point mutations for enhancing rate of clearance
09/12/2003WO2003074568A1 Individualized anti-cancer antibodies
09/12/2003WO2003074537A1 Compounds for use as surfactants
09/12/2003WO2003074474A2 Multiple-component solid phases containing at least one active pharmaceutical ingredient
09/12/2003WO2003074098A1 Modified phosphocalcic compound, injectable composition containing same
09/12/2003WO2003074090A2 Compositions of polymers
09/12/2003WO2003074089A1 Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof
09/12/2003WO2003074088A2 Coupling low-molecular substances to hydroxyalkyl starch
09/12/2003WO2003074087A1 Coupling proteins to a modified polysaccharide
09/12/2003WO2003074086A1 Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
09/12/2003WO2003074084A1 A pharmaceutical composition
09/12/2003WO2003074058A1 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery
09/12/2003WO2003074041A1 Pharmaceutical compositions
09/12/2003WO2003074038A1 Methods for treating diseases related to intraocular pressure
09/12/2003WO2003074036A1 Novel formulation
09/12/2003WO2003074034A1 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
09/12/2003WO2003074032A1 Oral administration form for difficulty soluble basic active ingredients which are applied orally
09/12/2003WO2003074029A1 Fast melt multiparticulate formulations for oral delivery
09/12/2003WO2003074027A2 Self emulsifying drug delivery systems for poorly soluble drugs
09/12/2003WO2003074025A2 Pressurised metered dose inhalers containing solutions of beta-2 agonists
09/12/2003WO2003074023A1 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
09/12/2003WO2003051333B1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
09/12/2003WO2003047630A3 Method for oxygen treatment of unsaturated carbon compounds, novel epoxy-structured material obtained by the method, apparatus for carrying out the method and a therapeutic composition using the material
09/12/2003WO2003041757A3 Catheter injectable depot compositions and uses thereof
09/12/2003WO2003041684A3 Injectable depot compositions and uses thereof
09/12/2003WO2003039596B1 Photodynamic therapy for the treatment of hair loss
09/12/2003WO2003034995A3 Integrin targeting compounds
09/12/2003WO2003033028A3 Multimeric proteins
09/12/2003WO2003033027A3 Dendrimers for use in targeted delivery
09/12/2003WO2003032814A3 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
09/12/2003WO2003020200A3 A novel pharmaceutical compound and methods of making and using same
09/12/2003WO2003017932B1 Compositions and methods for targeting cerebral circulation and treatment of headache
09/12/2003WO2002098874A3 Inhalation capsules
09/12/2003WO2002098465B1 Cell penetrating therapeutic agents
09/12/2003WO2002080979A3 Conjugate of hydroxyalkyl starch and an active agent
09/12/2003WO2002058732B1 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
09/12/2003WO2002043686A3 Acid cosmetic, dermatological and pharmaceutical agents
09/12/2003WO2002028362A3 Vaccine composition and stabilisation method
09/12/2003WO2002027317A3 Conjugates of defined stoichiometry
09/12/2003WO2002018572A3 Membrane penetrating peptides and uses thereof
09/12/2003WO2002017956A3 Stabilized fgf formulations containing reducing agents
09/12/2003WO2002005853A3 Compositions containing alpha-2-adrenergic agonist components
09/12/2003CA2818688A1 System and method for the production of recombinant glycosylated proteins in a prokaryotic host
09/12/2003CA2666005A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
09/12/2003CA2478425A1 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
09/12/2003CA2478424A1 Self emulsifying drug delivery systems for poorly soluble drugs
09/12/2003CA2478011A1 Bispecific antibody point mutations for enhancing rate of clearance
09/12/2003CA2477964A1 Liquid matrix transforming its phase in living body and oral liquid preparation
09/12/2003CA2477923A1 Multiple-component solid phases containing at least one active pharmaceutical ingredient
09/12/2003CA2477794A1 System and method for the production of recombinant glycosylated proteins in a prokaryotic host
09/12/2003CA2477392A1 Methods for treating diseases related to intraocular pressure
09/12/2003CA2476744A1 Solid pharmaceutical compositions comprising lumiracoxib
09/12/2003CA2476182A1 Conjugates of therapeutic or cytotoxic agents and biologically active peptides
09/12/2003CA2475370A1 Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof
09/12/2003CA2456077A1 Individualized anti-cancer antibodies
09/12/2003CA2455447A1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/11/2003WO2003074551A2 Conjugates of therapeutic or cytotoxic agents and biologically active peptides
09/11/2003WO2003074056A1 Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
09/11/2003WO2003074054A1 Ophthalmic composition comprising ascomycin
09/11/2003WO2003074024A1 Formoterol superfine formulation
09/11/2003US20030171573 Multivalently interactive molecular assembly, capturing agent, drug carrier, calcium chelating agent, and drug enhancer
09/11/2003US20030171555 Antitumor agents
09/11/2003US20030171554 Tumour necrosis factor peptide binding antibodies
1 ... 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 ... 1712